Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + total body irradiation + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intravenous, External Beam Radiation
01
Overview
This is a specific myeloablative preparative regimen developed by St. Jude Children's Research Hospital for use in pediatric and young adult patients with high-risk hematologic malignancies undergoing umbilical cord blood transplantation (UCBT). The regimen is designed to achieve profound myeloablation and immunosuppression to facilitate donor stem cell engraftment while eradicating residual malignant cells. It consists of a combination of the purine analog fludarabine (75 mg/m²), fractionated total body irradiation (TBI) at a dose of 10.0 to 12.0 Gy, and the alkylating agent cyclophosphamide (120 mg/kg). The regimen also includes the administration of mesna as a uroprotective agent to prevent hemorrhagic cystitis associated with high-dose cyclophosphamide. This protocol is typically evaluated in Phase 2 clinical trials for patients who lack a suitable HLA-matched related or unrelated donor.
- Other names
- St. Jude UCBT Preparative RegimenFlu/TBI/Cy regimenMyeloablative Preparative Regimen
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + total body irradiation + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + total body irradiation + cyclophosphamide.